Showing results (381-390 of 391) with videos related to
Sort By:
Pageof 40
Plos One|June 21, 2024
Effects of allopurinol and febuxostat on uric acid transport and transporter expression in human umbilical vein endothelial cellsKarel H van der Pol, Jan Koenderink, Jeroen J M W van den Heuvel, et al.Mucosal Immunology|March 5, 2015
Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axisC Ning, Y-Y Li, Y Wang, et al.Molecular Microbiology|March 19, 2016
Vital and dispensable roles of Plasmodium multidrug resistance transporters during blood- and mosquito-stage developmentSanna R Rijpma, Maarten van der Velden, Takeshi Annoura, et al.Journal of Pharmaceutical Sciences|February 5, 2021
Implementation of a Human Renal Proximal Tubule on a Chip for Nephrotoxicity and Drug Interaction StudiesMarianne K Vormann, Jelle Vriend, Henriëtte L Lanz, et al.Journal of Clinical Pharmacology|September 23, 2021
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic ModelingCarlijn H C Litjens, Laurens F M Verscheijden, Celine Bolwerk, et al.Cellular Microbiology|September 3, 2015
Multidrug ATP-binding cassette transporters are essential for hepatic development of Plasmodium sporozoitesSanna R Rijpma, Maarten van der Velden, Maria González-Pons, et al.Journal of Crohn'S & Colitis|June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.Journal of Crohn'S & Colitis|December 15, 2022
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel DiseaseFemke Crouwel, Melek Simsek, Marjon A de Boer, et al.Pageof 40